Cellectis S.A. (NASDAQ:CLLS) went up by 4.12% from its latest closing price compared to the recent 1-year high of $34.71. The company’s stock price has collected 0.15% of gains in the last five trading sessions. Press Release reported on 03/29/21 that Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
Is It Worth Investing in Cellectis S.A. (NASDAQ :CLLS) Right Now?
Plus, the 36-month beta value for CLLS is at 2.44. Opinions of the stock are interesting as 12 analysts out of 14 who provided ratings for Cellectis S.A. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $34.22. CLLS currently public float of 35.08M and currently shorts hold a 3.16% ratio of that float. Today, the average trading volume of CLLS was 423.77K shares.
CLLS’s Market Performance
CLLS stocks went up by 0.15% for the week, with a monthly drop of -6.51% and a quarterly performance of -25.40%, while its annual performance rate touched 122.66%. The volatility ratio for the week stands at 6.52% while the volatility levels for the past 30 days are set at 7.67% for Cellectis S.A.. The simple moving average for the period of the last 20 days is -0.00% for CLLS stocks with a simple moving average of -5.59% for the last 200 days.
Analysts’ Opinion of CLLS
Many brokerage firms have already submitted their reports for CLLS stocks, with Robert W. Baird repeating the rating for CLLS by listing it as a “Outperform.” The predicted price for CLLS in the upcoming period, according to Robert W. Baird is $39 based on the research report published on March 16th of the current year 2021.
Citigroup, on the other hand, stated in their research note that they expect to see CLLS reach a price target of $32, previously predicting the price at $15. The rating they have provided for CLLS stocks is “Buy” according to the report published on August 19th, 2020.
Robert W. Baird gave a rating of “Outperform” to CLLS, setting the target price at $20 in the report published on May 12th of the previous year.
CLLS Trading at -11.29% from the 50-Day Moving Average
After a stumble in the market that brought CLLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.69% of loss for the given period.
Volatility was left at 7.67%, however, over the last 30 days, the volatility rate increased by 6.52%, as shares surge +0.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.78% lower at present.
During the last 5 trading sessions, CLLS rose by +0.15%, which changed the moving average for the period of 200-days by +9.35% in comparison to the 20-day moving average, which settled at $20.25. In addition, Cellectis S.A. saw -25.20% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLLS
Current profitability levels for the company are sitting at:
- -126.81 for the present operating margin
- +50.95 for the gross margin
The net margin for Cellectis S.A. stands at -109.64. The total capital return value is set at -23.55, while invested capital returns managed to touch -22.61.
Based on Cellectis S.A. (CLLS), the company’s capital structure generated 38.71 points at debt to equity in total, while total debt to capital is 27.91. Total debt to assets is 22.72, with long-term debt to equity ratio resting at 36.28. Finally, the long-term debt to capital ratio is 26.16.
When we switch over and look at the enterprise to sales, we see a ratio of 14.37, with the company’s debt to enterprise value settled at 0.09. The receivables turnover for the company is 4.43 and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.06.